



## Letter to the Editor

**Letter to editor regarding “piR-36249 and DHX36 together inhibit testicular cancer cells progression by upregulating OAS2”**

A B S T R A C T

Several reports describing PIWI-interacting RNAs (piRNAs) in human cancer cells or in the bloodstream are affected by the presence of false positives in piRNA databases. A recent report suggested that piR-36249 regulates testicular cancer progression by engaging with DHX36 to regulate OAS2. However, piR-36249 is a tRNA-Cys 5' half capable of forming intermolecular G-quadruplexes. It is therefore expected that DHX36, a helicase with high affinity for DNA and RNA G-quadruplexes, was pulled down using piR-36249 mimicking probes. The suggestion of using piR-36249 as a therapeutic target for testicular cancer is therefore questionable, due to the consequences that tRNA inhibition could have on healthy cells.

*To the Editor,*

I have read the manuscript by Wang et al. recently published in *Noncoding RNA Research*, suggesting that the piR-36249/DHX36/OAS2 axis regulates testicular cancer progression [1]. While the paper includes several interesting experiments, I am afraid it is affected by the PIWI-interacting RNA (piRNA) annotation problem that is widespread in the mammalian somatic piRNA literature [2,3].

piR-36249 (DQ598183) is a tRNA-Cys 5' half. The same genomic region in chromosome 17 that is shown in Wang et al. [1] as the loci producing piR-36249 is annotated in the UCSC Genome Browser as tRNA-Cys, anticodon GCA (see HUGO or RepeatMasker tracks). Consistently, the sequence of piR-36249 is identical to the first 30 nucleotides of tRNA-Cys-GCA-2 based on the genomic tRNA database (<http://gtrnadb.ucsc.edu/>).

Like tRNA-Cys 5' halves, piR-36249/DQ598183 starts with 5 consecutive guanines. This 5' terminal oligoguanine (5' TOG) motif induces the tetramerization of tRNA-Cys 5' halves, due to the formation of intermolecular G-quadruplex structures [4,5]. Tetrameric tRNA-Cys 5' halves regulate translation by interacting with eIF4G [6,7]. The differences observed by Wang et al. in cell viability, proliferation and migration when using piR-36249 mimics vs. control oligonucleotides or inhibitors can therefore be explained by the lack of the 5' TOG motif in the control sequences. Additionally, while the biotinylated piR-36249 probe used for pull-down experiments contained the 5' TOG motif, the control probe did not. It is therefore not surprising that DHX36 was experimentally identified as a piR-36249 interactor [1], because DHX36 binds G-quadruplexes with extremely high affinity [8].

In their conclusion, Wang et al. state that their data supports piR-36249 as a novel therapeutic target in testicular cancer [1]. However, targeting a tRNA gene would probably be toxic.

This article [1] illustrates why avoiding mis-classifying noncoding RNA fragments as piRNAs is of paramount importance. While somatic piRNA expression is well documented in arthropods, mollusks, and birds [9–11], piRNA expression in human cancer and the presence of piRNAs in the bloodstream remains to be demonstrated (despite a conundrum of papers suggesting so).

We have introduced the term “miscellaneous piRNAs” (*m*-piRNAs) to contemplate the possibility of certain noncoding RNA fragments being associated with PIWI proteins under certain conditions [3]. However, no direct evidence linking piR-36249 and PIWI proteins was provided by Wang et al. so this piRNA should be considered a wrongly annotated tRNA-derived fragment rather than a canonical piRNA or an *m*-piRNA.

While results in Wang et al. are still valid, the interpretation of these results and the likelihood of using piR-36249 as a therapeutic target should be revisited.

**Declaration of competing interest**

The author has no competing interests regarding this submission.

**References**

- [1] Q. Wang, P. Chen, X. Wang, Y. Wu, K. Xia, X. Mu, Q. Xuan, J. Xiao, Y. He, W. Liu, X. Song, F. Sun, piR36249 and DHX36 together inhibit testicular cancer cells progression by upregulating OAS2, *NonCoding RNA Res* 8 (2023) 174–186.
- [2] J.P. Tosar, C. Rovira, A. Cayota, Non-coding RNA fragments account for the majority of annotated piRNAs expressed in somatic non-gonadal tissues, *Commun. Biol.* 1 (2018) 2.
- [3] J.P. Tosar, M.R. García-Silva, A. Cayota, Circulating SNORD57 rather than piR-54265 is a promising biomarker for colorectal cancer: common pitfalls in the study of somatic piRNAs in cancer, *RNA* 27 (2021) 403–410.
- [4] P. Ivanov, E. O'Day, M.M. Emara, G. Wagner, J. Lieberman, P. Anderson, G-quadruplex structures contribute to the neuroprotective effects of angiogenin-induced tRNA fragments, *Proc. Natl. Acad. Sci. U.S.A.* 111 (2014) 18201–18206.
- [5] S.M. Lyons, D. Gudanis, S.M. Coyne, Z. Gdaniec, P. Ivanov, Identification of functional tetramolecular RNA G-quadruplexes derived from transfer RNAs, *Nat. Commun.* 8 (2017) 1127.
- [6] P. Ivanov, M.M. Emara, J. Villen, S.P. Gygi, P. Anderson, Angiogenin-induced tRNA fragments inhibit translation initiation, *Mol. Cell.* 43 (2011) 613–623.
- [7] S.M. Lyons, P. Kharel, Y. Akiyama, S. Ojha, D. Dave, V. Tsvetkov, W. Merrick, P. Ivanov, P. Anderson, eIF4G has intrinsic G-quadruplex binding activity that is required for tRNA function, *Nucleic Acids Res.* 48 (2021) 6223–6233.
- [8] M.C. Chen, R. Tippana, N.A. Demeshkina, P. Murat, S. Balasubramanian, S. Myong, A.R. FerréD'amaré, Structural basis of G-quadruplex unfolding by the DEAH/RHA helicase DHX36, *Nature* 558 (2018).
- [9] J. Jehn, D. Gebert, F. Pipilescu, S. Stern, J.S.T. Kiefer, C. Hewel, D. Rosenkranz, PIWI genes and piRNAs are ubiquitously expressed in mollusks and show patterns of lineage-specific adaptation, *Commun. Biol.* 1 (2018) 137.

<https://doi.org/10.1016/j.ncrna.2023.08.007>

- [10] S.H. Lewis, K.A. Quarles, Y. Yang, M. Tanguy, L. Frézal, S.A. Smith, P.P. Sharma, R. Cordaux, C. Gilbert, I. Giraud, D.H. Collins, P.D. Zamore, E.A. Miska, P. Sarkies, F.M. Jiggins, Pan-arthropod, analysis reveals somatic piRNAs as an ancestral defence against transposable elements, *Nat. Ecol. Evol.* 2 (2018) 174–181.
- [11] R. Galton, K. Fejes-Toth, M. Bronner, Co-option of the piRNA pathway to regulate neural crest specification, *Sci. Adv.* 8 (2022).

Juan Pablo Tosar\*

Functional Genomics Laboratory, Institut Pasteur de Montevideo, Uruguay

Analytical Biochemistry Unit, Nuclear Research Center. School of Science,  
Universidad de la Repùblica, Uruguay

\* Functional Genomics Laboratory, Institut Pasteur de Montevideo,  
Uruguay.

E-mail address: [jptosar@pasteur.edu.uy](mailto:jptosar@pasteur.edu.uy).